HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Online-Only Appendix All Versions of this Article: db06-1384v1 57/2/405    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Simon, G. Articles by Atkinson, M. A. PubMed PubMed Citation Articles by Simon, G. Articles by Atkinson, M. A. Social Bookmarking                What's this?

Murine Antithymocyte Globulin Therapy Alters Disease Progression in NOD Mice by a Time-Dependent Induction of Immunoregulation

¹ Department of Pathology, University of Florida, Gainesville, Florida
² Department of Pediatrics, University of Florida, Gainesville, Florida
³ Department of Medicine, University of Florida, Gainesville, Florida
⁴ La Jolla Institute for Allergy and Immunology, La Jolla, California
⁵ Genzyme Corporation, Framingham, Massachusetts
⁶ Department of Medicine, University of Illinois-Chicago, Chicago, Illinois

Address correspondence and reprint requests to Mark A. Atkinson, Department of Pathology, University of Florida, 1600 SW Archer Rd., Gainesville, FL 32610. E-mail: atkinson{at}ufl.edu

Abbreviations: ALS, antilymphocyte serum; ATG, antithymocyte globulin; APC, antigen-presenting cell; G-CSF, granulocyte colony–stimulating factor; IL, interleukin; ILN, inguinal lymph node; PLN, pancreatic lymph node; Teff, effector T-cell; Treg, regulatory T-cell

OBJECTIVE—Antilymphocyte serum can reverse overt type 1 diabetes in NOD mice; yet, the therapeutic parameters and immunological mechanisms underlying the ability for this agent to modulate autoimmune responses against β-cells are unclear, forming the rationale for this investigation.

RESEARCH DESIGN AND METHODS—A form of antilymphocyte serum, rabbit anti-mouse thymocyte globulin (mATG), was utilized in a variety of in vivo and in vitro settings, each for the purpose of defining the physiological, immunological, and metabolic activities of this agent, with particular focus on actions influencing development of type 1 diabetes.

RESULTS—We observed that mATG attenuates type 1 diabetes development in an age-dependent fashion, only proving efficacious at disease onset or in the late pre-diabetic phase (12 weeks of age). When provided at 12 weeks of age, mATG reversed pancreatic insulitis, improved metabolic responses to glucose challenge, and rapidly increased frequency of antigen-presenting cells in spleen and pancreatic lymph nodes. Surprisingly, mATG therapy dramatically increased, in an age-dependent fashion, the frequency and the functional activity of CD4⁺CD25⁺ regulatory T-cells. Adoptive transfer/cotransfer studies of type 1 diabetes also support the concept that mATG treatment induces a stable and transferable immunomodulatory repertoire in vivo.

CONCLUSIONS—These findings indicate that an induction of immunoregulation, rather than simple lymphocyte depletion, contributes to the therapeutic efficacy of antithymocyte globulin and suggest that time-dependent windows for the ability to delay or reverse type 1 diabetes exist based on the capacity to enhance the functional activity of regulatory T-cells.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?